194 related articles for article (PubMed ID: 15379712)
1. Inhibitors of Tissue Factor. Factor VIIa for anticoagulant therapy.
Lazarus RA; Olivero AG; Eigenbrot C; Kirchhofer D
Curr Med Chem; 2004 Sep; 11(17):2275-90. PubMed ID: 15379712
[TBL] [Abstract][Full Text] [Related]
2. The N-terminal epidermal growth factor-like domain in factor IX and factor X represents an important recognition motif for binding to tissue factor.
Zhong D; Bajaj MS; Schmidt AE; Bajaj SP
J Biol Chem; 2002 Feb; 277(5):3622-31. PubMed ID: 11723140
[TBL] [Abstract][Full Text] [Related]
3. Role of the Gla and first epidermal growth factor-like domains of factor X in the prothrombinase and tissue factor-factor VIIa complexes.
Thiec F; Cherel G; Christophe OD
J Biol Chem; 2003 Mar; 278(12):10393-9. PubMed ID: 12529356
[TBL] [Abstract][Full Text] [Related]
4. Engineering exosite peptides for complete inhibition of factor VIIa using a protease switch with substrate phage.
Maun HR; Eigenbrot C; Lazarus RA
J Biol Chem; 2003 Jun; 278(24):21823-30. PubMed ID: 12657647
[TBL] [Abstract][Full Text] [Related]
5. New insight into how tissue factor allosterically regulates factor VIIa.
Eigenbrot C; Kirchhofer D
Trends Cardiovasc Med; 2002 Jan; 12(1):19-26. PubMed ID: 11796240
[TBL] [Abstract][Full Text] [Related]
6. A frequent human coagulation Factor VII mutation (A294V, c152) in loop 140s affects the interaction with activators, tissue factor and substrates.
Toso R; Pinotti M; High KA; Pollak ES; Bernardi F
Biochem J; 2002 Apr; 363(Pt 2):411-6. PubMed ID: 11931672
[TBL] [Abstract][Full Text] [Related]
7. A novel exosite on coagulation factor VIIa and its molecular interactions with a new class of peptide inhibitors.
Roberge M; Santell L; Dennis MS; Eigenbrot C; Dwyer MA; Lazarus RA
Biochemistry; 2001 Aug; 40(32):9522-31. PubMed ID: 11583151
[TBL] [Abstract][Full Text] [Related]
8. Roles of the membrane-interactive regions of factor VIIa and tissue factor. The factor VIIa Gla domain is dispensable for binding to tissue factor but important for activation of factor X.
Neuenschwander PF; Morrissey JH
J Biol Chem; 1994 Mar; 269(11):8007-13. PubMed ID: 8132522
[TBL] [Abstract][Full Text] [Related]
9. Crystal structure of active site-inhibited human coagulation factor VIIa (des-Gla).
Kemball-Cook G; Johnson DJ; Tuddenham EG; Harlos K
J Struct Biol; 1999 Oct; 127(3):213-23. PubMed ID: 10544046
[TBL] [Abstract][Full Text] [Related]
10. Factor VII mutant V154G models a zymogen-like form of factor VIIa.
Toso R; Bernardi F; Tidd T; Pinotti M; Camire RM; Marchetti G; High KA; Pollak ES
Biochem J; 2003 Feb; 369(Pt 3):563-71. PubMed ID: 12358603
[TBL] [Abstract][Full Text] [Related]
11. Substrate recognition by tissue factor-factor VIIa. Evidence for interaction of residues Lys165 and Lys166 of tissue factor with the 4-carboxyglutamate-rich domain of factor X.
Huang Q; Neuenschwander PF; Rezaie AR; Morrissey JH
J Biol Chem; 1996 Sep; 271(36):21752-7. PubMed ID: 8702971
[TBL] [Abstract][Full Text] [Related]
12. An unusual antibody that blocks tissue factor/factor VIIa function by inhibiting cleavage only of macromolecular substrates.
Fiore MM; Neuenschwander PF; Morrissey JH
Blood; 1992 Dec; 80(12):3127-34. PubMed ID: 1467519
[TBL] [Abstract][Full Text] [Related]
13. Tissue factor - a therapeutic target for thrombotic disorders.
Houston DS
Expert Opin Ther Targets; 2002 Apr; 6(2):159-74. PubMed ID: 12223078
[TBL] [Abstract][Full Text] [Related]
14. Four loops of the catalytic domain of factor viia mediate the effect of the first EGF-like domain substitution on factor viia catalytic activity.
Jin J; Perera L; Stafford D; Pedersen L
J Mol Biol; 2001 Apr; 307(5):1503-17. PubMed ID: 11292356
[TBL] [Abstract][Full Text] [Related]
15. Protease nexin-2/Amyloid beta-protein precursor regulates factor VIIa and the factor VIIa-tissue factor complex.
Mahdi F; Rehemtulla A; Van Nostrand WE; Bajaj SP; Schmaier AH
Thromb Res; 2000 Aug; 99(3):267-76. PubMed ID: 10942793
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the interaction between the light chain of factor VIIa and tissue factor.
Persson E
FEBS Lett; 1997 Aug; 413(2):359-63. PubMed ID: 9280313
[TBL] [Abstract][Full Text] [Related]
17. Binding of Zn2+ to a Ca2+ loop allosterically attenuates the activity of factor VIIa and reduces its affinity for tissue factor.
Petersen LC; Olsen OH; Nielsen LS; Freskgård PO; Persson E
Protein Sci; 2000 May; 9(5):859-66. PubMed ID: 10850795
[TBL] [Abstract][Full Text] [Related]
18. Model of a ternary complex between activated factor VII, tissue factor and factor IX.
Chen SW; Pellequer JL; Schved JF; Giansily-Blaizot M
Thromb Haemost; 2002 Jul; 88(1):74-82. PubMed ID: 12152682
[TBL] [Abstract][Full Text] [Related]
19. Interaction of activated factor VII and active site-inhibited activated factor VII with tissue factor.
Sørensen BB; Rao LV
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S67-71. PubMed ID: 9819031
[TBL] [Abstract][Full Text] [Related]
20. Selection and characterization of a new class of peptide exosite inhibitors of coagulation factor VIIa.
Dennis MS; Roberge M; Quan C; Lazarus RA
Biochemistry; 2001 Aug; 40(32):9513-21. PubMed ID: 11583150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
